| ATG003 Eye Drops - Recruiting |
 |
 |
 Share
ATG003 Eye DropsThis study is investigating the use of an eye drop in patients who are already getting Lucentis or Avastin. It is a double-masked, randomized, placebo-controlled study of the safety and effectiveness of ATG003 (topical mecamylamine) in patients receiving maintenance injections of either Lucentis or Avastin. The phase II study is recruiting 60 patients to receive either a dose of ATG003 or a placebo, while continuing the Lucentis or Avastin treatment. All patients will be treated for up to 48 weeks, during which time they will be monitored to assess the drug's safety, tolerability, and efficacy. The sponsor is CoMentis and the study takes place in Texas. For information, This e-mail address is being protected from spambots. You need JavaScript enabled to view it Kim Erby or call him at 650-869-7607 |
Search
Get News!
SIGN UP NOW
To receive the "AMD Update" and keep up-to-date with the latest research & treatment options:
For Email Newsletters you can trust